复发头颈鳞癌纳武利尤单抗治疗中寡进展的再程放疗:一例报告
本文报告一例复发头颈鳞状细胞癌(HNSCC)患者在纳武利尤单抗治疗期间出现两次后续寡进展,均位于既往未照射区域,接受再程放疗后成功控制且未中断纳武利尤单抗。作者提出免疫检查点抑制剂(ICI)与再程放疗在寡进展性疾病中可能存在空间协同效应。
要点
- 复发HNSCC纳武利尤单抗治疗中可出现寡进展模式。
- 两次寡进展病灶均位于既往未照射区域,再程放疗未中断纳武利尤单抗。
- 作者假设ICI与再程放疗存在空间协同效应。
核心结论
- 复发HNSCC患者在纳武利尤单抗治疗中出现寡进展时,对既往未照射区域的寡进展病灶行再程放疗可成功控制且不中断免疫治疗。
- 作者假设ICI与再程放疗在寡进展性疾病中存在空间协同效应。
研究设计与样本
- 本文为病例报告,报告一例复发HNSCC患者在纳武利尤单抗治疗期间出现两次后续寡进展并接受再程放疗的临床过程。
主要发现
- 患者出现两次后续寡进展,均位于既往未照射区域。
- 两次寡进展均经再程放疗成功治疗,且未中断纳武利尤单抗。
临床怎么用
- 对免疫治疗中出现的寡进展,可考虑对未照射病灶行再程放疗而不中断ICI,但需个体化评估。
局限性
- 本文为单例病例报告,结论属假设性,不能推广至所有复发HNSCC患者。
- 原文未报告再程放疗的剂量、分次、疗效评价标准及随访时长等具体参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) represent a recently introduced class of agents active in head and neck squamous cell carcinoma (HNSCC). For a subgroup of patients with recurrent or metastatic disease, long-term benefit can be achieved: maintaining a sustained response to immunotherapy is therefore a critical factor for its efficacy at an individual level. In analogy to targeted agents, a limited pattern of progression, or "oligoprogression", can occur. For locally recurrent HNSCC, the potential biologic interplay between the efficacy of ICIs and the design of radiation fields chosen for primary treatment is currently unknown. Here, we report on a patient who presented two subsequent oligoprogressions successfully treated with re-irradiation without interrupting Nivolumab. Both oligoprogressive lesions developed in previously unirradiated areas. We hypothesize the existence of a synergistic effect with optimal spatial cooperation between ICIs and re-irradiation for oligoprogressive disease under immunotherapy.
引用
- Bonomo P, Lucidi S, Desideri I, et al. Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report. Clin Transl Radiat Oncol. 2020. PMID: 32368625. doi:10.1016/j.ctro.2020.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。